Research programme: induced pluripotent stem cell therapeutics - Center for iPS Cell Research Application/Takeda

Drug Profile

Research programme: induced pluripotent stem cell therapeutics - Center for iPS Cell Research Application/Takeda

Alternative Names: iPS cell based therapeutics - CiRA/Takeda; NGLY1 deficiency therapeutic - CiRA/Takeda/RIKEN

Latest Information Update: 13 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Center for iPS Cell Research and Application; Takeda
  • Developer Center for iPS Cell Research and Application; RIKEN; Takeda
  • Class Stem cell therapies
  • Mechanism of Action Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer; Diabetes mellitus; Heart failure; Inborn genetic disorders; Neurological disorders

Most Recent Events

  • 31 Mar 2017 Center for iPS Cell Research and Application, Takeda and RIKEN agree to co-develop induced stem cell therapeutics in Japan for Inborn genetic disorders
  • 31 Mar 2017 Early research in Inborn genetic disorders in Japan (Parenteral)
  • 17 Apr 2015 Early research in Cancer in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top